Physician profile
Isabel Sarinas Manuel
NPI 1396892048
$389.69
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $42.62 · 2022: $69.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $143.78 | 2019 | |
| Alkermes, INC. | $88.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $37.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.67 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $30.67 | 2019-2020 | |
| Allergan, INC. | $29.99 | 2020 | |
| Lundbeck LLC | $14.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.